Assenagon Asset Management S.A. boosted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 13.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 19,918 shares of the biopharmaceutical company’s stock after acquiring an additional 2,285 shares during the period. Assenagon Asset Management S.A.’s holdings in Alnylam Pharmaceuticals were worth $4,687,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently modified their holdings of ALNY. Huntington National Bank increased its stake in shares of Alnylam Pharmaceuticals by 91.8% in the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 45 shares during the last quarter. Hollencrest Capital Management bought a new stake in Alnylam Pharmaceuticals during the 3rd quarter worth $29,000. Washington Trust Advisors Inc. bought a new stake in Alnylam Pharmaceuticals during the 3rd quarter worth $42,000. True Wealth Design LLC grew its position in shares of Alnylam Pharmaceuticals by 15,300.0% in the 3rd quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 153 shares during the last quarter. Finally, Harvest Fund Management Co. Ltd bought a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at about $45,000. Institutional investors own 92.97% of the company’s stock.
Insider Transactions at Alnylam Pharmaceuticals
In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 5,219 shares of the firm’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $1,309,864.62. Following the sale, the chief executive officer now owns 78,880 shares of the company’s stock, valued at $19,797,302.40. This trade represents a 6.21 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CMO Pushkal Garg sold 1,682 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $422,148.36. Following the sale, the chief marketing officer now owns 17,457 shares of the company’s stock, valued at approximately $4,381,357.86. This trade represents a 8.79 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 10,122 shares of company stock valued at $2,540,455. 1.50% of the stock is currently owned by corporate insiders.
Analyst Ratings Changes
Get Our Latest Report on Alnylam Pharmaceuticals
Alnylam Pharmaceuticals Stock Down 1.2 %
ALNY opened at $246.27 on Tuesday. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $304.39. The company has a market cap of $31.76 billion, a PE ratio of -94.00 and a beta of 0.34. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64. The company has a 50 day moving average of $245.95 and a 200 day moving average of $259.84.
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The firm had revenue of $500.90 million during the quarter, compared to the consensus estimate of $532.91 million. During the same period in the previous year, the business posted $1.15 EPS. The business’s quarterly revenue was down 33.3% compared to the same quarter last year. On average, sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.21 EPS for the current year.
Alnylam Pharmaceuticals Profile
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.
See Also
- Five stocks we like better than Alnylam Pharmaceuticals
- How to trade using analyst ratings
- 3 Stocks to Gain From Donald Trump’s External Revenue Service
- How to invest in marijuana stocks in 7 stepsÂ
- AMD: Loop Capital’s Buy Rating Reinforces Investor Confidence
- 5 discounted opportunities for dividend growth investors
- Momentum Is Building for Qualcomm to Have a Strong Run in 2025
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.